At the 5th FDA-Drug Industry Association (DIA) Workshop on 'Pharmacogenomics in Drug Development and Regulatory Decision Making', track four focused on the current thinking and issues in the co-development of therapeutic drugs or biologics, and their companion diagnostic products. Identification and validation of genomic and other biomarkers are becoming important components of drug-development strategies, and recent successes show the power of personalized approaches to change the benefit-risk paradigm for new drugs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/pgs.10.141 | DOI Listing |
Publication Analysis
Top Keywords
development regulatory
8
regulatory strategies
4
strategies drug
4
drug diagnostic
4
diagnostic co-development
4
co-development 5th
4
5th fda-drug
4
fda-drug industry
4
industry association
4
association dia
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!